Crispr Therapeutics

Crispr Therapeutics

Yahoo Finance • 2 days ago

Cathie Wood sells $4 million of surging AI stock

Cathie Wood, chief of Ark Investment Management, often trims her biggest winners after sharp rallies. This week, she's selling Tempus AI (TEM), taking some shares off the table after the healthcare AI stock surged nearly 30% in days and b... Full story

Yahoo Finance • 5 days ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 5 days ago

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Gene editing is emerging as a potentially transformative approach to medicine because it seeks to address disease at its genetic source rather than primarily managing downstream symptoms. Unlike conventional therapies that may require chro... Full story

Yahoo Finance • 14 days ago

Cathie Wood sells $11.6 million of surging tech stock

Cathie Wood, chief of Ark Investment Management, often locks in gains when her favorite tech stocks surge. That's what she's doing with Palantir Technologies (PLTR), trimming her position after the stock jumped more than 30% over the past... Full story

Yahoo Finance • 25 days ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR... Full story

Yahoo Finance • 26 days ago

Cathie Wood Is Leaning Harder Into Her Highest-Conviction Themes

This article first appeared on GuruFocus. ARK Innovation ETF (ARKK, Financials), the actively managed fund focused on disruptive technology, increased exposure to space, artificial intelligence and autonomous systems during the final week... Full story

Yahoo Finance • 27 days ago

Cathie Wood sells $5.5 million of surging tech stock

Cathie Wood, head of Ark Investment Management, likes to lock in gains when her tech darlings rally. That's exactly what she's doing with Snowflake, trimming her position after the cloud software stock surged nearly 10% over the past five... Full story

Yahoo Finance • 28 days ago

CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a tradi... Full story

Yahoo Finance • 29 days ago

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

Key Points CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon. The stock is somewhat risky given the possibility of clinical failures. 10 stocks we like better than CRISPR Therap... Full story

Yahoo Finance • last month

3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside

Investing in stocks with modest valuations can set investors up for some significant returns in the long run. While there is more risk involved in putting money into smaller, less-established businesses, the upside can also be considerable... Full story

Yahoo Finance • last month

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strok... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $22.8 million of surging tech stock

Cathie Wood, CEO of Ark Investment Management, is known for investing in high-growth tech companies. She'll even add to positions amid strong gains, and that's what she just did, adding shares of a megacap stock that has surged 14.8% over... Full story

Yahoo Finance • 2 months ago

3 Reasons to Buy CRISPR Therapeutics Stock

Key Points CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market. It has expanded beyond its core gene-editing pla... Full story

Yahoo Finance • 2 months ago

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

Key Points CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pip... Full story

Yahoo Finance • 2 months ago

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key Points CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic diso... Full story

Yahoo Finance • 2 months ago

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?

Key Points Arcutis Biotherapeutics is rapidly scaling its Zoryve dermatology line with revenue doubling in its most recent fiscal year. Vertex Pharmaceuticals maintains a dominant position in cystic fibrosis while successfully expanding i... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $11.5 million of battered tech stock

Cathie Wood, chief of Ark Investment Management, likes to double down on her favorite tech stocks when the prices are falling, hoping for a bargain. That's what Wood just did, adding shares of Coinbase after weeks of tumbling. In 2025, W... Full story

Yahoo Finance • 2 months ago

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Key Points CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by cystic fibrosis treatments... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $9.6 million of megacap tech stock

Cathie Wood, chief of Ark Investment Management, likes to double down on her favorite tech stocks, especially when the prices are falling. That's what she just did, buying a megacap tech stock amid a broader market sell-off. In 2025, the... Full story

Yahoo Finance • 2 months ago

The Best Stocks to Invest $1,000 in Right Now

Long-term investing is about building your portfolio brick by brick. That could mean adding money weekly, monthly, or whenever you have extra cash on hand. How much you can invest at a time is all relative, but $1,000 is a nice round numbe... Full story